134 results
8-K
EX-99.1
KALA
Kala Bio Inc.
14 May 24
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
-based compensation costs and employee related costs.
R&D Expenses: For the quarter ended March 31, 2024, research and development (R&D) expenses were … and employee-related costs, as we advance the clinical development of KPI-012, and an increase in other research and development costs.
Gain on Fair Value
S-8
EX-5.1
KALA
Kala Bio Inc.
29 Mar 24
Registration of securities for employees
8:21am
and Restated 2017 Equity Incentive Plan; Amended and Restated 2017 Employee Stock Purchase Plan; Inducement Stock Option Awards (June 23, 2023 – January … Employee Stock Purchase Plan (the “ESPP”) and (iii) 5,485 shares of Common Stock issuable pursuant to nonqualified stock option agreements, providing
S-8
gio1w kbw
29 Mar 24
Registration of securities for employees
8:21am
S-8
gi4in7e
29 Mar 24
Registration of securities for employees
8:21am
8-K
EX-99.1
fxdxe66ioorkjx 0k
29 Mar 24
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
8:01am
8-K
EX-10.1
7ml88dm495m
26 Mar 24
Entry into a Material Definitive Agreement
8:30am
8-K
EX-10.1
79nr9rcgpjdom
22 Dec 23
Entry into a Material Definitive Agreement
8:22am
8-K
EX-99.1
z4d6l6 mg6hfq
13 Nov 23
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:05am